Skip to main content

A Blueprint to Advance Colorectal Cancer Immunotherapies.

Publication ,  Journal Article
Le, DT; Hubbard-Lucey, VM; Morse, MA; Heery, CR; Dwyer, A; Marsilje, TH; Brodsky, AN; Chan, E; Deming, DA; Diaz, LA; Fridman, WH; Goldberg, RM ...
Published in: Cancer Immunol Res
November 2017

Immunotherapy is rapidly becoming a standard of care for many cancers. However, colorectal cancer had been generally resistant to immunotherapy, despite features in common with sensitive tumors. Observations of substantial clinical activity for checkpoint blockade in colorectal cancers with defective mismatch repair (microsatellite instability-high tumors) have reignited interest in the search for immunotherapies that could be extended to the larger microsatellite stable (MSS) population. The Cancer Research Institute and Fight Colorectal Cancer convened a group of scientists, clinicians, advocates, and industry experts in colorectal cancer and immunotherapy to compile ongoing research efforts, identify gaps in translational and clinical research, and provide a blueprint to advance immunotherapy. We identified lack of a T-cell inflamed phenotype (due to inadequate T-cell infiltration, inadequate T-cell activation, or T-cell suppression) as a broad potential explanation for failure of checkpoint blockade in MSS. The specific cellular and molecular underpinnings for these various mechanisms are unclear. Whether biomarkers with prognostic value, such as the immunoscores and IFN signatures, would also predict benefit for immunotherapies in MSS colon cancer is unknown, but if so, these and other biomarkers for measuring the potential for an immune response in patients with colorectal cancer will need to be incorporated into clinical guidelines. We have proposed a framework for research to identify immunologic factors that may be modulated to improve immunotherapy for colorectal cancer patients, with the goal that the biomarkers and treatment strategies identified will become part of the routine management of colorectal cancer. Cancer Immunol Res; 5(11); 942-9. ©2017 AACR.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Immunol Res

DOI

EISSN

2326-6074

Publication Date

November 2017

Volume

5

Issue

11

Start / End Page

942 / 949

Location

United States

Related Subject Headings

  • Immunotherapy
  • Humans
  • Colorectal Neoplasms
  • Animals
  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1112 Oncology and Carcinogenesis
  • 1107 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Le, D. T., Hubbard-Lucey, V. M., Morse, M. A., Heery, C. R., Dwyer, A., Marsilje, T. H., … Benson, A. B. (2017). A Blueprint to Advance Colorectal Cancer Immunotherapies. Cancer Immunol Res, 5(11), 942–949. https://doi.org/10.1158/2326-6066.CIR-17-0375
Le, Dung T., Vanessa M. Hubbard-Lucey, Michael A. Morse, Christopher R. Heery, Andrea Dwyer, Thomas H. Marsilje, Arthur N. Brodsky, et al. “A Blueprint to Advance Colorectal Cancer Immunotherapies.Cancer Immunol Res 5, no. 11 (November 2017): 942–49. https://doi.org/10.1158/2326-6066.CIR-17-0375.
Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, et al. A Blueprint to Advance Colorectal Cancer Immunotherapies. Cancer Immunol Res. 2017 Nov;5(11):942–9.
Le, Dung T., et al. “A Blueprint to Advance Colorectal Cancer Immunotherapies.Cancer Immunol Res, vol. 5, no. 11, Nov. 2017, pp. 942–49. Pubmed, doi:10.1158/2326-6066.CIR-17-0375.
Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O’Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB. A Blueprint to Advance Colorectal Cancer Immunotherapies. Cancer Immunol Res. 2017 Nov;5(11):942–949.

Published In

Cancer Immunol Res

DOI

EISSN

2326-6074

Publication Date

November 2017

Volume

5

Issue

11

Start / End Page

942 / 949

Location

United States

Related Subject Headings

  • Immunotherapy
  • Humans
  • Colorectal Neoplasms
  • Animals
  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1112 Oncology and Carcinogenesis
  • 1107 Immunology